UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of June 2026 Commission File No.:001-35773

Commission File No.:001-35773

REDHILL BIOPHARMA LTD.

(Translation of registrant’s name into English)

21 Ha'arba'a Street, Tel Aviv, 6473921, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Attached hereto and incorporated herein by reference ~~herein~~ ~~are~~is the ~~following:~~notice of the annual general meeting of RedHill Biopharma Ltd. scheduled for July 28, 2026.

Attached hereto and incorporated by reference herein is a press release issued by the Registrant entitled: “RedHill Biopharma Announces Up To $19.4 Million Private Placement”.

This Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845), on June 29, 2023 (File No. 333-273001), on June 20, 2024 (File No. 333-280327), on March 25, 2025 (File No. 333-286082) and on January 22, 2026 (File No. 333-292879), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on August 4, 2023 (File No. 333-273709), on October 13, 2023 (File No. 333-274957), as amended, and on August 9, 2024 (File No. 333-281417).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	REDHILL BIOPHARMA LTD.
	(the "Registrant")
Date: June 18, 2026	By:	/s/ Dror Ben-Asher
Date: June 22, 2026	By:	/s/ Dror Ben-Asher
	Name:	Dror Ben-Asher
	Title:	Chief Executive Officer

2REDHILL BIOPHARMA LTD. 21 Ha’arba’a Street

~~Press~~Tel-Aviv ~~Release~~6473921

~~RedHill Biopharma Announces Up To $19.4 Million~~Israel

~~Private Placement~~NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

$6To ~~million~~be ~~upfront~~held ~~with~~on upJuly to28, ~~approximately $13.4 million of potential aggregate gross proceeds~~2026

~~upon~~The Annual General Meeting of Shareholders of RedHill Biopharma Ltd. (the ~~exercise~~“Company”), inwill ~~full~~be held at the offices of ~~warrants~~the Company, 21 Ha’arba’a Street, 16ᵗʰ Floor, Tel-Aviv, Israel, on July 28, 2026, at 3:00 p.m. Israel time, or at any adjournments thereof (the “General Meeting”), for the following purposes:

~~TEL AVIV, ISRAEL & RALEIGH, N~~1.~~C.,~~ ~~June 18,~~To ~~2026 /PRNewswire/~~ re--appoint ~~RedHill~~Kesselman ~~Biopharma~~& ~~Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”)~~Kesselman, acertified ~~specialty~~public ~~biopharmaceutical~~accountants ~~company,~~in ~~today~~Israel ~~announced~~and ~~that it has entered into~~ a ~~definitive~~member ~~agreement for the purchase and sale~~ of anPricewaterhouseCoopers ~~aggregate~~International ~~of 8~~Limited,~~571,429~~ ~~American~~as ~~Depositary Shares (“ADSs”) (or ADS equivalents in lieu thereof), each ADS representing ten thousand (10,000) ordinary shares of~~ the Company,’s ~~series~~auditors ~~A-1~~for ~~warrants~~the toyear ~~purchase up~~2026 ~~to an aggregate of 8,571,429 ADSs~~ and ~~series~~for ~~A-2 warrants to purchase up to~~ an ~~aggregate~~additional ofperiod ~~8,571,429~~until ~~ADSs,~~the atnext aAnnual ~~combined~~General ~~purchase price~~Meeting; ~~of $0.70 per ADS (or ADS equivalent in lieu thereof)~~ and ~~accompanying~~to ~~warrants~~inform inthe ashareholders ~~private placement. The Series A-1 warrants have an exercise price~~ of ~~$0.86 per ADS, are exercisable immediately and have a term of five years following~~ the ~~Effectiveness~~aggregate ~~Date~~compensation ~~(as~~paid ~~defined below),~~to ~~and~~ the ~~Series~~auditors ~~A-2~~for ~~warrants have an exercise price of $0.70 per ADS, are exercisable immediately and have a term of 18 months following~~ the ~~Effectiveness~~year ~~Date.~~ended ~~The~~December ~~private placement is expected to close on June 22~~31, ~~2026, subject to the satisfaction of customary closing conditions.~~2025;

H2.C To approve the re-election of Mr. ~~Wainwright~~Rick &D. CoScruggs and Dr. isShmuel ~~acting~~Cabilly asto the ~~exclusive placement~~board ~~agent~~of directors of the Company (the “Board of Directors”) for an additional three-year term until the ~~offering.~~annual general meeting to be held in 2029; and

~~The~~3. ~~gross~~To ~~proceeds~~approve to the ~~Company~~engagement ~~from~~by ~~this offering are expected to be approximately $6 million, before deducting~~ the ~~placement~~Company ~~agent’s~~of ~~fees and other offering expenses payable by the Company~~Mr. ~~The~~Dror ~~potential~~Ben-Asher ~~additional~~to ~~gross~~serve ~~proceeds~~as to the Company's ~~from~~Chairman ~~the~~of ~~series A-1 warrants and~~ the ~~series~~Board ~~A-2 warrants, if fully exercised on a cash basis, will be approximately $13.4 million. No assurance can be given that any~~ of ~~the~~Directors ~~series~~and ~~warrants will be exercised, or that~~ the Company's ~~will~~Chief ~~receive~~Executive ~~cash proceeds from the exercise of the series warrants~~Officer.

3In addition, shareholders at the General Meeting will have an opportunity to review and ask questions regarding the financial statements of the Company for the fiscal year ended December 31, 2025.

The Company ~~intends~~is tocurrently ~~use~~unaware aof ~~portion~~any ofother matters that may be raised at the ~~net~~General Meeting. Should any ~~proceeds~~ other tomatters ~~support~~be aproperly ~~potential~~raised ~~strategic~~at ~~product~~the ~~acquisition~~General ~~and~~Meeting, the ~~balance~~persons ~~for~~designated ~~working~~as ~~capital,~~proxies ~~research~~shall ~~and~~vote ~~development~~according ~~and~~to ~~general corporate~~their ~~purposes~~own judgment on those matters.

NoOnly ~~definitive~~holders ~~acquisition~~of ~~agreement~~record ~~has~~of ~~been executed~~ADSs, ~~and~~ ~~any~~evidenced ~~such~~by ~~transaction~~American ~~would~~Depositary ~~remain~~Receipts ~~subject~~issued toby ~~completion~~The Bank of ~~definitive~~New ~~documentation,~~York ~~financing~~Mellon at ~~and~~the ~~other~~close ~~customary~~of ~~conditions.~~business ~~There can~~on June 23, 2026 shall be noentitled ~~assurance~~to ~~that~~receive ~~any~~notice ~~such~~of ~~transaction~~and ~~will~~to bevote ~~completed~~at the General Meeting.

The ~~securities~~Board ~~described above were offered in a private placement under Section 4(a)(2)~~ of ~~the~~Directors ~~Securities~~recommends ~~Act~~that ofyou ~~1933,~~vote ~~as amended (the~~ “~~Securities Act~~FOR”), ~~and/or Regulation D promulgated thereunder and, along with~~ the ~~ordinary shares of the Company represented by ADSs underlying the warrants~~proposals, ~~have~~as ~~not~~specified ~~been registered~~on ~~under~~ the ~~Securities~~enclosed ~~Act~~form ~~or applicable state securities laws. Accordingly, the securities issued in the private placement and ordinary shares~~ of the Company represented by ADSs underlying the warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities lawsproxy. Pursuant to a registration rights agreement with the investors, the Company has agreed to file a resale registration statement covering the securities described above (such date of effectiveness of the resale registration statement, the “Effectiveness Date”).

~~This~~ADS ~~press~~holders ~~release~~should ~~shall~~return ~~not~~their ~~constitute~~proxies anby offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the ~~registration~~date orset ~~qualification~~forth ~~under~~on ~~the~~their ~~securities~~form ~~laws~~ of ~~any such state or other jurisdiction~~proxy.

~~About~~Shareholders ~~RedHill~~wishing ~~Biopharma~~ to express their position on an agenda item for this General Meeting may do so by submitting a written statement (“Position Statement”) to the Company’s offices, c/o Mr. Razi Ingber, at 21 Ha’arba’a Street, Tel-Aviv, 6473921 Israel, by no later than July 17, 2026. Any Position Statement received, that is in accordance with the guidelines set by the Israel Companies Law, will be furnished to the U.S. Securities and Exchange Commission (the “Commission”) on Form 6-K, and will be made available to the public on the Commission’s website at http://www.sec.gov.

~~RedHill~~ ~~Biopharma~~If ~~Ltd.~~within ~~(Nasdaq: RDHL) is~~half aan ~~specialty~~hour ~~biopharmaceutical~~from ~~company~~the ~~primarily~~time ~~focused~~appointed ~~on U.S. development and commercialization of drugs~~ for ~~gastrointestinal diseases, infectious diseases and oncology. RedHill promotes~~ the ~~FDA-approved~~General ~~gastrointestinal drug Talicia®~~Meeting, ~~for the~~ ~~treatment of Helicobacter pylori (H. pylori) infection in adults[i], with~~ a ~~U.S.~~quorum ~~co-commercialization~~is ~~agreement~~not ~~with Cumberland Pharmaceuticals (Nasdaq: CPIX). RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640)~~present, athe ~~first-in-class, orally administered sphingosine kinase-2~~General ~~(SPHK2)~~ Meeting ~~selective~~shall ~~inhibitor~~be ~~with~~adjourned ~~anti-inflammatory,~~to ~~antiviral,~~the ~~metabolic~~next ~~and~~business ~~anticancer~~day ~~activity,~~following ~~targeting~~the ~~multiple~~day ~~indications~~of ~~with U.S. government~~the ~~and~~scheduled ~~academic~~General ~~collaborations intended for medical countermeasure development including for Ebola virus disease~~Meeting, ~~radiation~~at ~~exposure indications~~the ~~such~~same astime ~~GI-Acute Radiation Syndrome (GI-ARS), a Phase 2/3 program for hospitalized COVID-19,~~ and ~~an ongoing Phase 2 study in prostate cancer in combination with Bayer’s darolutamide; (ii) RHB-102 (Bekinda®)~~place, ~~with~~or aat ~~planned~~another ~~Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance~~day, ~~positive~~time ~~results from a U.S. Phase 3 study for acute gastroenteritis~~ and ~~gastritis,~~ ~~positive~~place ~~results~~prescribed ~~from~~by athe ~~U.S.~~Board Phase 2 study for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of ~~RHB-104,~~Directors ~~with~~in a ~~planned~~ ~~Phase~~notification 2to ~~study~~the for Crohn's disease (based on RHB-104's positive Phase 3 Crohn's disease study results); and (iv) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, including COVID-19 and also targeting multiple cancer and inflammatory gastrointestinal diseasesshareholders.

~~More~~This ~~information~~Notice ~~about~~and the ~~Company~~documents ismentioned ~~available~~therein, as well as the proposed resolutions on the agenda, will be at made available to the public on the Company's website http://www.redhillbio.com and on the Commission’s website at http:/ ~~X.com~~/~~RedHillBio~~www.sec.gov.

4By Order of the Board of Directors, Dror Ben-Asher Chairman of the Board of Directors

~~Forward~~Tel-Aviv, ~~Looking Statements~~Israel

~~This~~June ~~press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities~~22, ~~stock~~ analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words and include, among others, the consummation of the offering and the satisfaction of customary closing conditions related to the offering, the use of proceeds therefrom, the potential exercise of the series warrants and potential proceeds therefrom, potential acquisition of strategic products, statements regarding the potential submission of Talicia® for UK Marketing Authorisation and any approval thereof and statements regarding the potential effects of Talicia® in the treatment of Helicobacter pylori infection. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: market and other conditions, the risk that the MAA submission for Talicia may not be approved; the risk that the Company will not succeed in its enforcement action against Kukbo, and if successful may not recover all or any of awards granted by the New York Supreme Court; the risk that opaganib does not receive a priority review voucher, marketing exclusivity or accelerated development and review times; the risk that opaganib is not accepted into Ebola virus disease control programs, or if accepted, that it does not demonstrate efficacy; the risk that development of RHB-204 for Crohn’s disease may not be completed, or if completed may not be approved or may not achieve commercial success; the risk that opaganib is not effective against the indications for which we develop our products; the risk that RHB-102 (Bekinda) does not effectively reduce GLP-1/GIP-related nausea, vomiting and diarrhea; the risk regarding the Company's ability to regain and maintain compliance with Nasdaq's listing requirements, including the minimum bid price requirement; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that the Company will not receive future milestone payments under its existing agreements or that they will be less than anticipated; the risk of current uncertainty regarding U.S. government research and development funding and that the U.S. government is under no obligation to continue to support development of our products and can cease such support at any time; the risk that acceptance onto the RNCP Product Development Pipeline or other governmental and non-governmental development programs will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for its programs; the risk that the Company's development programs and studies may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional studies may be required; the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of any necessary commercial companion diagnostics; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates and Talicia; (v) the Company's ability to successfully commercialize and promote Talicia; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) the Company’s ability to collect on its judgment against Kukbo; (xiii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiv) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; (xv) competition from other companies and technologies within the Company's industry; and (xvi) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on April 27, 2026. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.

Company contact: Adi Frish Chief Corporate & Business Development Officer RedHill Biopharma [email protected]

Category: R&D

1Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: www.Talicia.com.

Filing Compare · RedHill Biopharma Ltd.